Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 1,019 Shares of Stock
by Amy Steele · The Cerbat GemEdwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Daniel Lippis sold 1,019 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $83.98, for a total transaction of $85,575.62. Following the sale, the vice president owned 33,682 shares of the company’s stock, valued at $2,828,614.36. This trade represents a 2.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Down 0.8%
EW stock traded down $0.66 during midday trading on Monday, reaching $83.32. 3,302,606 shares of the company’s stock traded hands, compared to its average volume of 5,757,119. The company has a market cap of $48.04 billion, a price-to-earnings ratio of 44.32, a P/E/G ratio of 2.11 and a beta of 0.87. The firm’s fifty day moving average price is $82.08 and its 200-day moving average price is $82.54. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $87.89.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. Edwards Lifesciences’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Edwards Lifesciences
A number of hedge funds and other institutional investors have recently made changes to their positions in EW. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp lifted its holdings in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after purchasing an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. raised its position in shares of Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after purchasing an additional 17,625 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on EW shares. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Robert W. Baird upped their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. UBS Group reiterated a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Barclays reiterated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Finally, Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.
Read Our Latest Stock Report on EW
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.